Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Cadence Design SystemsSynopsysDocuSignElectronic ArtsVeeva Systems
SymbolNASDAQ:CDNSNASDAQ:SNPSNASDAQ:DOCUNASDAQ:EANYSE:VEEV
Price Information
Current Price$147.26$260.77$231.93$141.05$273.07
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.51.61.72.11.7
Analysis Score2.32.43.42.32.3
Community Score2.92.82.63.23.1
Dividend Score0.00.00.01.70.0
Ownership Score1.71.71.71.71.7
Earnings & Valuation Score0.61.30.61.91.3
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$140.92$284.82$273.55$153.34$299.87
% Upside from Price Target-4.31% downside9.22% upside17.95% upside8.72% upside9.81% upside
Trade Information
Market Cap$41.10 billion$39.73 billion$44.78 billion$40.57 billion$41.57 billion
Beta1.051.10.880.920.84
Average Volume1,771,162938,5893,258,5612,751,183980,615
Sales & Book Value
Annual Revenue$2.34 billion$3.69 billion$973.97 million$5.54 billion$1.10 billion
Price / Sales17.5910.7845.987.3337.65
Cashflow$4.35 per share$6.25 per shareN/A$5.55 per share$1.91 per share
Price / Cash33.8641.71N/A25.40143.05
Book Value$7.51 per share$32.37 per share$3.01 per share$25.76 per share$11.17 per share
Price / Book19.618.0677.055.4824.45
Profitability
Net Income$988.98 million$664.35 million$-208,360,000.00$3.04 billion$301.12 million
EPS$3.53$4.27($0.94)$4.76$1.62
Trailing P/E Ratio38.2561.21N/A31.41127.60
Forward P/E Ratio74.3755.48N/A29.82129.42
P/E Growth4.645.07N/A2.839.41
Net Margins42.68%18.03%-16.83%23.51%24.88%
Return on Equity (ROE)48.31%14.81%-30.14%17.85%15.73%
Return on Assets (ROA)28.21%8.79%-7.60%12.11%12.12%
Dividend
Annual PayoutN/AN/AN/A$0.68N/A
Dividend YieldN/AN/AN/A0.48%N/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/A14.29%N/A
Years of Consecutive Dividend GrowthN/AN/AN/A1 YearsN/A
Debt
Debt-to-Equity Ratio0.14%0.02%1.14%0.05%N/A
Current Ratio1.55%1.19%1.01%2.75%4.44%
Quick Ratio1.51%1.10%1.01%2.75%4.44%
Ownership Information
Institutional Ownership Percentage83.86%86.11%72.76%87.95%77.54%
Insider Ownership Percentage2.58%1.84%5.06%0.92%14.38%
Miscellaneous
Employees8,80015,0363,9099,8003,501
Shares Outstanding279.07 million152.37 million193.09 million287.63 million152.22 million
Next Earnings Date4/26/2021 (Confirmed)5/19/2021 (Estimated)6/3/2021 (Estimated)5/11/2021 (Confirmed)5/27/2021 (Estimated)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
To 2026, Clinical Trial Management Systems Market Size in North America to grow at a CAGR of over 14.2%To 2026, Clinical Trial Management Systems Market Size in North America to grow at a CAGR of over 14.2%
marketwatch.com - April 16 at 11:23 PM
Parexel and Veeva Systems collaborate to advance clinical trial technologyParexel and Veeva Systems collaborate to advance clinical trial technology
clinicaltrialsarena.com - April 16 at 8:21 AM
Parexel and Veeva Partner Aim to Accelerate Clinical TrialsParexel and Veeva Partner Aim to Accelerate Clinical Trials
appliedclinicaltrialsonline.com - April 15 at 7:30 PM
Jonathan Faddis Sells 261 Shares of Veeva Systems Inc. (NYSE:VEEV) StockJonathan Faddis Sells 261 Shares of Veeva Systems Inc. (NYSE:VEEV) Stock
americanbankingnews.com - April 15 at 4:54 PM
Parexel and Veeva Partner to Accelerate Clinical TrialsParexel and Veeva Partner to Accelerate Clinical Trials
finance.yahoo.com - April 15 at 2:24 PM
FY2022 Earnings Forecast for Veeva Systems Inc. Issued By Piper Sandler (NYSE:VEEV)FY2022 Earnings Forecast for Veeva Systems Inc. Issued By Piper Sandler (NYSE:VEEV)
americanbankingnews.com - April 14 at 10:26 AM
Veeva continues to find white space to expand the life sciences market, says CFO BowmanVeeva continues to find 'white space' to expand the life sciences market, says CFO Bowman
cmlviz.com - April 13 at 11:07 PM
Veeva Systems Inc. (NYSE:VEEV) EVP Sells $615,289.52 in StockVeeva Systems Inc. (NYSE:VEEV) EVP Sells $615,289.52 in Stock
americanbankingnews.com - April 13 at 5:00 PM
Is VEEV Stock A Buy or Sell?Is VEEV Stock A Buy or Sell?
finance.yahoo.com - April 12 at 7:31 PM
If You Like EPS Growth Then Check Out Veeva Systems (NYSE:VEEV) Before Its Too LateIf You Like EPS Growth Then Check Out Veeva Systems (NYSE:VEEV) Before It's Too Late
finance.yahoo.com - April 8 at 6:18 PM
Insider Selling: Veeva Systems Inc. (NYSE:VEEV) SVP Sells 320 Shares of StockInsider Selling: Veeva Systems Inc. (NYSE:VEEV) SVP Sells 320 Shares of Stock
americanbankingnews.com - April 5 at 11:28 PM
Veeva Systems Inc. (NYSE:VEEV) CFO Sells $45,482.58 in StockVeeva Systems Inc. (NYSE:VEEV) CFO Sells $45,482.58 in Stock
americanbankingnews.com - April 5 at 11:28 PM
Veeva Systems Inc. (NYSE:VEEV) CMO Sells $93,624.96 in StockVeeva Systems Inc. (NYSE:VEEV) CMO Sells $93,624.96 in Stock
americanbankingnews.com - April 5 at 11:28 PM
Thomas D. Schwenger Sells 822 Shares of Veeva Systems Inc. (NYSE:VEEV) StockThomas D. Schwenger Sells 822 Shares of Veeva Systems Inc. (NYSE:VEEV) Stock
americanbankingnews.com - April 5 at 10:42 PM
Is Veeva (VEEV) a Solid Growth Stock? 3 Reasons to Think " Yes "Is Veeva (VEEV) a Solid Growth Stock? 3 Reasons to Think " Yes "
finance.yahoo.com - April 1 at 6:23 PM
Veeva (VEEV) Down 0.8% Since Last Earnings Report: Can It Rebound?Veeva (VEEV) Down 0.8% Since Last Earnings Report: Can It Rebound?
finance.yahoo.com - April 1 at 1:22 PM
Veeva Systems (NYSE:VEEV) Raised to Neutral at UBS GroupVeeva Systems (NYSE:VEEV) Raised to Neutral at UBS Group
americanbankingnews.com - March 31 at 9:14 AM
Veeva Systems (VEEV) Buy Rating Reaffirmed at Raymond JamesVeeva Systems' (VEEV) Buy Rating Reaffirmed at Raymond James
americanbankingnews.com - March 31 at 9:14 AM
Veeva Systems (NYSE:VEEV) Stock Rating Reaffirmed by Raymond JamesVeeva Systems (NYSE:VEEV) Stock Rating Reaffirmed by Raymond James
marketbeat.com - March 31 at 8:00 AM
Veeva Systems Stock Is Believed To Be Fairly ValuedVeeva Systems Stock Is Believed To Be Fairly Valued
ca.finance.yahoo.com - March 27 at 3:22 PM
TFS HealthScience Standardizes on Veeva Vault Clinical Operations Suite to Accelerate Clinical DevelopmentTFS HealthScience Standardizes on Veeva Vault Clinical Operations Suite to Accelerate Clinical Development
finance.yahoo.com - March 25 at 7:51 AM
Should Investors Be Worried About Veeva Systems Slowdown?Should Investors Be Worried About Veeva Systems' Slowdown?
finance.yahoo.com - March 24 at 10:27 AM
Boehringer Ingelheim Makes Rapid Shift to Digital Engagement with Veeva CRM Engage MeetingBoehringer Ingelheim Makes Rapid Shift to Digital Engagement with Veeva CRM Engage Meeting
finance.yahoo.com - March 24 at 10:27 AM
Baron Asset Fund: “Veeva (VEEV) Remains Well Positioned From Digitalization”Baron Asset Fund: “Veeva (VEEV) Remains Well Positioned From Digitalization”
finance.yahoo.com - March 23 at 1:56 PM
Veeva (VEEV) Partners With Impel, Boosts Cloud-Based Offerings (Revised)Veeva (VEEV) Partners With Impel, Boosts Cloud-Based Offerings (Revised)
finance.yahoo.com - March 22 at 7:35 AM
Tendo Systems Builds Radical Collaborations to Help Transform HealthcareTendo Systems Builds Radical Collaborations to Help Transform Healthcare
omaha.com - March 16 at 10:51 PM
Veeva Systems (NYSE:VEEV) Stock a Buy: Cloud Software for Life SciencesVeeva Systems (NYSE:VEEV) Stock a Buy: Cloud Software for Life Sciences
marketbeat.com - December 23 at 5:20 PM
DateCompanyBrokerageAction
3/1/2021Cadence Design SystemsNeedham & Company LLCBoost Price Target
3/1/2021Cadence Design SystemsCredit Suisse GroupBoost Price Target
3/1/2021Cadence Design SystemsRoyal Bank of CanadaBoost Price Target
3/1/2021Cadence Design SystemsBenchmarkReiterated Rating
2/23/2021Cadence Design SystemsDA DavidsonBoost Price Target
2/16/2021Cadence Design SystemsKeyCorpBoost Price Target
2/10/2021Cadence Design SystemsWells Fargo & CompanyBoost Price Target
1/11/2021Cadence Design SystemsBank of AmericaDowngrade
12/9/2020Cadence Design SystemsJPMorgan Chase & Co.Upgrade
10/14/2020Cadence Design SystemsUBS GroupBoost Price Target
7/21/2020Cadence Design SystemsRobert W. BairdBoost Price Target
12/16/2020SynopsysMizuhoReiterated Rating
3/29/2021DocuSignDaiwa Capital MarketsInitiated Coverage
3/18/2021DocuSignEvercore ISIUpgrade
3/18/2021DocuSignMorgan StanleyBoost Price Target
3/3/2021DocuSignCitigroupInitiated Coverage
2/17/2021DocuSignWedbushBoost Price Target
1/4/2021DocuSignPiper SandlerUpgrade
12/4/2020DocuSignCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
12/4/2020DocuSignDeutsche Bank AktiengesellschaftBoost Price Target
12/4/2020DocuSignPritchard CapitalBoost Price Target
12/4/2020DocuSignJMP SecuritiesBoost Price Target
2/5/2021Electronic ArtsBMO Capital MarketsBoost Price Target
2/4/2021Electronic ArtsAtlantic SecuritiesDowngrade
2/3/2021Electronic ArtsMKM PartnersBoost Price Target
2/3/2021Electronic ArtsRaymond JamesInitiated Coverage
2/3/2021Electronic ArtsCowenBoost Price Target
2/3/2021Electronic ArtsBarclaysBoost Price Target
2/2/2021Electronic ArtsTruistBoost Price Target
1/24/2021Electronic ArtsThe Goldman Sachs GroupUpgrade
11/9/2020Electronic ArtsStifel NicolausLower Price Target
3/9/2021Veeva SystemsSVB LeerinkBoost Price Target
(Data available from 4/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.